Advance oligonucleotide therapeutics

Discover our newly available lipophilic modifiers

2’-O-C16 CPG

CPG used to add a lipophilic 2’-O-hexadecyl lipophilic modification to the 3' end of an oligonucleotide.

2’-O-C16 CE-Phosphoramidite

Phosphoramidite for the incorporation of a 2’-O-hexadecyl lipophilic chain modification internally or at the 5' end of an oligonucleotide.

3'-Docosanamido C7 CPG

CPG used to add a lipophilic docosanoate chain to the 3' end of an oligonucleotide.

3’-Dodecanamido-C7 CPG

CPG used to add a lipophilic dodecanoic saturated fatty acid chain to the 3' end of an oligonucleotide.

Dodecanamido-C7 CE-Phosphoramidite

hosphoramidite for the incorporation of a lipophilic dodecanoic chain internally or at the 5' end of an oligonucleotide, with a C7 spacer.

3’-Palmitamido-C7 CPG

CPG used to add a lipophilic palmitoyl-modifier to the 3' end of an oligonucleotide, with a C7 spacer.

3’-Palmitamido-C7 CE-Phosphoramidite

Phosphoramidite for the incorporation of a lipophilic palmitoyl-modifier internally or at the 5' end of an oligonucleotide, with a C7 spacer.

Tri-GalNAc-TEG C7 CPG

CPG used to add a trivalent GalNAc ligand to the 3' end of an oligonucleotide.

Toolbox for oligonucleotide therapeutic development

We are proud to support the advancement of nucleic acid therapeutics with our diverse portfolio of oligonucleotide modifications, solid supports and reagents.

More than 100 drugs, approved or in development, are made using at least one of our reagents.

With convenient online ordering, reliable technical support and industry-leading products, LGC Biosearch Technologies™ simplifies the path from drug discovery to commercialisation.

Backbone and other modifications

Backbone and other modifications can increase the stability, binding affinity and nuclease resistance of a therapeutic oligonucleotide. Biosearch Technologies offers common backbone modifications, including:

Locked nucleic acids (LNA)
Peptide nucleic acids (PNA)
Alkyl phosphoramidites
H-phosphonates
Sulphurising reagents
Vinyl phosphonates

Explore all backbone modifications and vinyl phosphonates.

Nuclease-resistant modifications

Nuclease resistance is essential for the therapeutic efficacy of antisense oligonucleotide (ASO) or small interfering RNA (siRNA) applications. Nuclease-resistant modifications can be introduced to reduce or eliminate an oligonucleotide’s susceptibility to in vivo enzymatic destruction. Biosearch Technologies offers these common modifications to enhance the nuclease resistance of ASOs and siRNAs:

3'-DNA
AlkA
Dideoxy
2'-F solid supports
2'-OMe solid supports
Reverse synthesis solid supports
2'-F phosphoramidites
2'-OMe phosphoramidites
Reverse synthesis phosphoramidites

Explore all nuclease-resistant modifications

Cell delivery and uptake modifications

In addition to stabilising RNA constructs in vivo, efficacious nucleic acid therapeutics require efficient, targeted delivery to the appropriate tissues. Optimised cell delivery platforms can help reduce dosage requirements, increase efficiency and minimise toxicity with more accurate tissue targeting. Biosearch Technologies offers the following solutions to increase cell delivery and uptake of ASOs and siRNAs:

Lipophilic modifiers
GalNAc modifiers
Vitamin modifiers

EXPLORE CELL DELIVERY AND UPTAKE MODIFICATIONS

Solid supports

Solid support performance can be a significant factor in reducing oligonucleotide synthesis cost and ensuring a quality product. Our diverse range of industry-leading solid supports, including controlled pore glass (CPG) products, are designed to meet the requirements of nearly any oligonucleotide synthesis application.

Biosearch Technologies’ CPG is the gold-standard solid support used in all sectors of the therapeutics market. Our advanced CPG production techniques improve control of particle size and shape, pore size, pore volume and specific surface area. These physical parameters influence solution exchange behaviour, ligand loading and distribution and reaction kinetics to increase the efficiency, purity, and reproducibility of syntheses. Our manufacturing process optimises solid supports for the latest therapeutic oligonucleotide classes including LNA, delivery enhancing lipid ligands, siRNA and single-guide RNA (sgRNA) for CRISPR applications. We offer solid supports with various pore sizes, from 500 Å to 3000 Å, and functionalised nucleoside loadings. Our portfolio of 2'-OMe and 2’-F CPGs with a variety of pore sizes and linkers offer consistent reliability for a wide range of therapeutic applications.

Explore 2’OMe, 2’F and unmodified solid supports.

Why work with us?

Our extensive product portfolio includes modifications critical to optimising the efficacy of therapeutic applications.
Our technical team has expertise in a wide range of therapeutic processes, including ASOs, siRNAs, immunostimulatory oligos, aptamers, miRNAs and miRNA antagonists, as well as guide RNAs for CRISPR applications.
A long history of research and development supporting therapeutic applications, combined with our technical expertise, enables us to tackle complex nucleic acid therapeutics challenges.
We follow ISO quality manufacturing standards to deliver the most reliable, consistent products for a variety of therapeutic applications.